Influence of (+)-cyanidanol-3 on the leukocyte migration inhibition test carried out in the presence of purified protein derivative and hepatitis B surface antigen
- PMID: 7251131
- PMCID: PMC351461
- DOI: 10.1128/iai.32.2.432-437.1981
Influence of (+)-cyanidanol-3 on the leukocyte migration inhibition test carried out in the presence of purified protein derivative and hepatitis B surface antigen
Abstract
It has been shown that (+)-cyanidanol-3, therapeutically administered during the course of acute hepatitis B, is able to favor the elimination of hepatitis B surface antigen (HBsAg) from the blood. This observation suggests that (+)-cyanidanol-3 might stimulate the cell-mediated immune response, since it is known that this type of response is responsible for elimination of the virus. In the present study, the possible action of (+)-cyanidanol-3 on this type of immunity was investigated by adding the substance in vitro to leukocyte migration inhibition tests, performed with the antigens purified protein derivative (PPD) and HBsAg and with leukocytes from individuals sensitized to these antigens. In normal individuals sensitized to PPD, the addition of (+)-cyanidanol-3 amplified the inhibition of migration by 7.0% (P less than 0.05). In patients previously infected by hepatitis B virus and sensitized to HBsAg, the addition of (+)-cyanidanol-3 amplified the migration inhibition by 10.5% (P less than 0.05). A trend to a dose-response relation was observed with the antigen PPD. (+)-Cyanidanol-3 did not modify leukocyte migration in the absence of an antigen. (+)-Cyanidanol-3 therefore seems capable of amplifying the cell-mediated immune response as measured by the leukocyte migration inhibition test. It is thus possible that it favors the elimination of HBsAg in patients by this mechanism.
Similar articles
-
Influence of palmitoyl-3-catechin and heptyl-3-catechin on the leucocyte migration inhibition test carried out in the presence of PPD and hepatitis B surface antigen (HBsAg).Int J Immunopharmacol. 1985;7(1):87-92. doi: 10.1016/0192-0561(85)90013-x. Int J Immunopharmacol. 1985. PMID: 3997321
-
[Studies of an assay system for dialyzable leukocyte extracts (DLE)--influence of DLE on leukocyte migration inhibition test by HBsAg].Hokkaido Igaku Zasshi. 1985 Sep;60(5):763-8. Hokkaido Igaku Zasshi. 1985. PMID: 3908264 Japanese.
-
Lack of leukocyte migration inhibition by hepatitis B antigen and normal nonspecific immunoreactivity in asymptomatic carriers.J Infect Dis. 1976 Nov;134(5):505-9. doi: 10.1093/infdis/134.5.505. J Infect Dis. 1976. PMID: 993619
-
Lack of leukocyte migration inhibition by hepatitis B surface antigen in hepatocellular carcinoma patients.Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi. 1979 Sep;12(3):86-92. Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi. 1979. PMID: 94850
-
[On the molecular mechanism of action of (+)-cyanidanol-3 (author's transl)].Arzneimittelforschung. 1979;29(5):720-4. Arzneimittelforschung. 1979. PMID: 387044 Review. German.
Cited by
-
Activation of suppressor function of human peripheral blood T cells by (+)cyanidanol-3: its application to chronic active liver diseases.Clin Exp Immunol. 1983 May;52(2):430-6. Clin Exp Immunol. 1983. PMID: 6222856 Free PMC article.
-
Treatment of chronic hepatitis B with recombinant leukocyte interferon and cyanidanol.Gastroenterol Jpn. 1988 Feb;23(1):44-8. doi: 10.1007/BF02918855. Gastroenterol Jpn. 1988. PMID: 3350278
-
Immune response to purified non-A, non-B hepatitis-related antigen demonstrated by leukocyte migration inhibition in patients recovering from the infection.Infection. 1986 Jan-Feb;14(1):13-6. doi: 10.1007/BF01644803. Infection. 1986. PMID: 2420723
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources